Factors Associated with the Use of Drug-Eluting Stents in Patients Presenting with Acute ST-Segment Elevation Myocardial Infarction

Cardiology Research and Practice

Volumn 2015, Issue , 2015, Pages

  Chavez, Jose F ^a   Doll, Jacob A ^a   Mediratta, Anuj ^a   Maffessanti, Francesco ^a   Friant, Janet ^a   Paul, Jonathan D ^a   Blair, John E A ^a   Nathan, Sandeep ^a   Jolly, Neeraj ^b   Shah, Atman P ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ACUTE DISEASE; ADULT; AGED; ALCOHOL ABUSE; ANTICOAGULATION; ARTICLE; BARE METAL STENT; CARDIOGENIC SHOCK; CHRONIC KIDNEY FAILURE; COCAINE DEPENDENCE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG USE; FEMALE; HEALTH INSURANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCOME; INTRAAORTIC BALLOON PUMP; MAJOR CLINICAL STUDY; MALE; MEDICAID; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SHOCK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TERTIARY CARE CENTER; THROMBECTOMY DEVICE; TREATMENT DURATION; URBAN AREA; URBAN POPULATION; VERY ELDERLY;

EID: 84935890288     PISSN: 20908016     EISSN: 20900597     Source Type: Journal    
DOI: 10.1155/2015/528753     Document Type: Article

References (30)

1. D.-W. Park, S.-C. Yun, S.-W. Lee, et al., "Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents, " JACC: Cardiovascular Interventions, vol. 1, no. 5, pp. 494-503, 2008.
2. A. J. Kirtane, A. Gupta, S. Iyengar, et al., "Safety and efficacy of drug-eluting and bare metal stents: comprehensive metaanalysis of rand omized trials and observational studies, " Circulation, vol. 119, no. 25, pp. 3198-3206, 2009.
3. E. di Lorenzo, R. Sauro, A. Varricchio, et al., "Benefits of drugeluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) rand omized trial, " The American Heart Journal, vol. 158, no. 4, pp. e43-e50, 2009.
4. S. Bangalore, S. Kumar, M. Fusaro, et al., "Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from rand omized trials, " Circulation, vol. 125, no. 23, pp. 2873-2891, 2012.
5. J. L. Anderson, "2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, " Circulation, vol. 127, no. 4, pp. e362-e425, 2013.
6. J. Conigliaro, J. Whittle, C. B. Good, et al., "Understand ing racial variation in the use of coronary revascularization procedures: the role of clinical factors, " Archives of Internal Medicine, vol. 160, no. 9, pp. 1329-1335, 2000.
7. N. R. Kressin and L. A. Petersen, "Racial differences in the use of invasive cardiovascular procedures: review of the literature and prescription for future research, " Annals of Internal Medicine, vol. 135, no. 5, pp. 352-366, 2001.
8. B. D. Smedley and A. R. Nelson, Eds., Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care, National Academies Press, Washington, DC, USA, 2002.
9. P. W. Groeneveld, P. A. Heidenreich, and A. M. Garber, "Racial disparity in cardiac procedures and mortality among long-term survivors of cardiac arrest, " Circulation, vol. 108, no. 3, pp. 286-291, 2003.
10. S. V. Rao, R. E. Shaw, R. G. Brindis, et al., "Patterns and outcomes of drug-eluting coronary stent use in clinical practice, " American Heart Journal, vol. 152, no. 2, pp. 321-326, 2006.
11. A. F. Sonel, C. B. Good, J. Mulgund, et al., "Racial variations in treatment and outcomes of black and white patients with highrisk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients SupressAdverseOutcomesWith Early Implementation of the ACC/AHA Guidelines?), " Circulation, vol. 111, no. 10, pp. 1225-1232, 2005.
12. E. L. Hannan, M. Racz, G. Walford, et al., "Differences in utilization of drug-eluting stents by race and payer, " The American Journal of Cardiology, vol. 100, no. 8, pp. 1192-1198, 2007.
13. J. Kao, R. Vicuna, J. A. House, J. S. Rumsfeld, H. H. Ting, and J. A. Spertus, "Disparity in drug-eluting stent utilization by insurance type, " American Heart Journal, vol. 156, no. 6, pp. 1133-1140, 2008.
14. M. G. Cohen, G. C. Fonarow, E. D. Peterson, et al., "Racial and ethnic differences in the treatment of acute myocardial infarction: findings from the get with the guidelines-coronary artery disease program, " Circulation, vol. 121, no. 21, pp. 2294-2301, 2010.
15. R. S. Kumar, P. S. Douglas, E. D. Peterson, et al., "Effect of race and ethnicity on outcomes with drug-eluting and bare metal stents: results in 423 965 patients in the linked national cardiovascular data registry and centers for medicare & medicaid services payer databases, " Circulation, vol. 127, no. 13, pp. 1395-1403, 2013.
16. G. N. Levine, E. R. Bates, J. C. Blankenship, et al., "2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the society for cardiovascular angiography and interventions, " Journal of the American College of Cardiology, vol. 58, no. 24, pp. e44-e122, 2011.
17. I. Iakovou, T. Schmidt, E. Bonizzoni, et al., "Incidence, predictors and outcome of thrombosis after succesful implantation of drug-eluting stents, " The Journal of the American Medical Association, vol. 293, no. 17, pp. 2126-2130, 2005.
18. J. A. Spertus, R. Kettelkamp, C. Vance, et al., "Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry, " Circulation, vol. 113, no. 24, pp. 2803-2809, 2006.
19. D.-W. Park, S.-W. Park, K.-H. Park, et al., "Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up, " The American Journal of Cardiology, vol. 98, no. 3, pp. 352-356, 2006.
20. M. Pfisterer, H. P. B.-L. Rocca, P. T. Buser, et al., "Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents, " Journal of the American College of Cardiology, vol. 48, no. 12, pp. 2584-2591, 2006.
21. E. L. Eisenstein, K. J. Anstrom, D. F. Kong, et al., "Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation, " Journal of the AmericanMedical Association, vol. 297, no. 2, pp. 159-168, 2007.
22. A. P. Amin, E. Mukhopadhyay, S. Nathan, S. Napan, and R. F. Kelly, "Association of medical noncompliance and long-term adverse outcomes, aftermyocardial infarction in a minority and uninsured population, " Translational Research, vol. 154, no. 2, pp. 78-89, 2009.
23. A. S. Quadros, D. I. Welter, F. O. Camozzatto, et al., "Identifying patients at risk for premature discontinuation of thienopyridine after coronary stent implantation, " The American Journal of Cardiology, vol. 107, no. 5, pp. 685-689, 2011.
24. J. M. Hodgson, R. K. Bottner, L. W. Klein, et al., "Drugeluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues, " Catheterization and Cardiovascular Interventions, vol. 62, no. 1, pp. 1-17, 2004.
25. M. A. Gaglia Jr., D. H. Steinberg, T. L. Pinto Slottow, et al., "Racial disparities in outcomes following percutaneous coronary intervention with drug-eluting stents, " American Journal of Cardiology, vol. 103, no. 5, pp. 653-658, 2009.
26. M. A. Gaglia, R. Torguson, Z. Xue, et al., "Insurance type influences the use of drug-eluting stents, " JACC: Cardiovascular Interventions, vol. 3, no. 7, pp. 773-779, 2010.
27. M. A. Gaglia Jr., R. Torguson, Z. Xue, et al., "Effect of insurance type on adverse cardiac events after percutaneous coronary intervention, " American Journal of Cardiology, vol. 107, no. 5, pp. 675-680, 2011.
28. M. A. Gaglia Jr., D. M. Shavelle, H. Tun, et al., "African-American patients are less likely to receive drug-eluting stents during percutaneous coronary intervention, " Cardiovascular Revascularization Medicine, vol. 15, no. 4, pp. 214-218, 2014.
29. L. Osterberg and T. Blaschke, "Adherence to medication, " The New England Journal of Medicine, vol. 353, no. 5, pp. 487-497, 2005.
30. J. J. Vlasnik, S. L. Aliotta, and B. DeLor, "Medication adherence: factors influencing compliance with prescribed medication plans, " Case Manager, vol. 16, no. 2, pp. 47-51, 2005.